Publications by authors named "Mark Holdbrook"
Significance: Patients with Demodex blepharitis have a considerable symptomatic burden that negatively impacts their daily activities and well-being. Despite chronic manifestations of and problems associated with blepharitis that resulted in multiple visits to eye care providers, Demodex blepharitis remained underdiagnosed or misdiagnosed.
Purpose: This study aimed to evaluate the effect of Demodex blepharitis on patients' daily activities and well-being.
Article Synopsis
- This study evaluated the long-term effects of lotilaner ophthalmic solution, 0.25%, for treating Demodex blepharitis, involving 239 patients who completed a prior study and returned for follow-ups at 180 and 365 days post-treatment.
- Results showed a significantly higher number of patients in the lotilaner group with fewer collarettes (indicators of infestation) compared to the control group, with improvement continuing even after treatment ended, and only mild adverse events reported.
- The conclusions suggest that the treatment remains effective over a year, with no significant long-term safety issues, indicating that the benefits of lotilaner may extend beyond the initial treatment period.
Article Synopsis
- The study aims to assess the safety and effectiveness of lotilaner ophthalmic solution 0.25% in treating Demodex blepharitis compared to a placebo (vehicle).
- In a randomized, double-masked clinical trial involving 412 participants, patients were split into two groups: one receiving lotilaner and the other receiving a vehicle without the active ingredient, over 6 weeks.
- Results showed that the lotilaner group had significantly better outcomes in terms of collarette cure, mite eradication, and associated symptoms compared to the control group, indicating its efficacy in treating the condition.
Purpose: To evaluate the impact of blepharitis on patients' daily activities and quality of life.
Patients And Methods: In this multicenter, observational, prospective, IRB-approved study, 311 blepharitis patients aged ≥18 years were included. blepharitis was diagnosed based on the presence of ≥1.
Article Synopsis
- The study aimed to assess the safety and effectiveness of lotilaner ophthalmic solution (0.25%) in treating Demodex blepharitis, compared to a control vehicle.
- In a randomized clinical trial involving 421 patients, those using lotilaner showed significantly better results in key outcomes such as collarette cure and mite eradication over 43 days.
- The findings suggest that the lotilaner solution is both safe and effective, with most patients reporting comfort during use and only mild adverse effects.
Article Synopsis
- The study focused on assessing the effectiveness and safety of lotilaner ophthalmic solution (0.25% eyedrops) for treating blepharitis compared to a placebo (vehicle).
- A total of 54 participants were involved in a double-blind trial, receiving either the lotilaner solution or the control solution twice a day for 42 days, measuring outcomes like collarette cure and mite eradication.
- Results showed a significantly higher success rate in achieving collarette cure (80% vs. 15.8%), mite eradication (73.3% vs. 21.1%), and composite cure (73.3% vs. 10.5%) in the lotilaner group, indicating it is a safe
Article Synopsis
- A study was conducted to evaluate the safety and effectiveness of a 0.25% lotilaner ophthalmic solution for treating blepharitis in 15 patients, focusing on symptoms like collarettes on the lids and mite density.
- After 28 days of treatment, significant improvements were observed, with collarette grades dropping and mite densities decreasing, leading to 57.1% of eyes showing complete mite eradication.
- The treatment was well tolerated with no reported adverse events, and the positive effects lasted until at least Day 90, suggesting it could be a promising option for managing blepharitis.
Article Synopsis
- * Results showed a 72.2% rate of collarette elimination and a 77.8% rate of mite eradication by day 42, with significant reductions in mean collarette grade and mite density.
- * Participants tolerated the treatment well, experiencing only mild and temporary adverse effects, indicating that the topical solution is a promising option for managing blepharitis.
Article Synopsis
- The study aimed to assess the safety and effectiveness of lotilaner ophthalmic solution, 0.25%, for treating blepharitis caused by Demodex infestation, compared to a control vehicle.
- Conducted as a phase II randomized controlled trial with 60 participants, subjects were treated for 28 days, with measures taken at multiple follow-up points to evaluate improvements in symptoms and reactions.
- Results showed significant reductions in symptoms and mite presence in the treatment group, with no serious side effects, indicating that lotilaner is both safe and effective for this condition.
Purpose: To evaluate the safety and effectiveness of the intranasal tear neurostimulator (ITN) in improving dry eye symptoms assessed in a controlled adverse environment (CAE®).
Methods: Study 1: Multicenter, subject-masked, randomized-sequence, crossover design. Single intranasal (active) and extranasal (control) ITN administration during CAE exposure.
Purpose: This study evaluated the tear concentration and safety of levofloxacin ophthalmic solution 1.5%.
Methods: Healthy adult volunteers (N = 125) received a single initial two-drop bilateral dose of either levofloxacin 1.